MCID: EHL001
MIFTS: 56

Ehlers-Danlos Syndrome malady

Categories: Genetic diseases, Rare diseases, Skin diseases, Eye diseases, Bone diseases, Fetal diseases, Cardiovascular diseases, Oral diseases

Aliases & Classifications for Ehlers-Danlos Syndrome

About this section

Aliases & Descriptions for Ehlers-Danlos Syndrome:

Name: Ehlers-Danlos Syndrome 10 68 45 23 47 12 36 35 65
Eds 68 45 23
Ehlers Danlos Disease 23 24
Elastic Skin 10 47
 
Ehlers Danlos Syndrome 45
Cutis Hyperelastica 10
Ed Syndrome 45

Classifications:



External Ids:

Disease Ontology10 DOID:13359
ICD1027 Q79.6
ICD9CM29 756.83
MeSH36 D004535
NCIt42 C34568
UMLS65 C0013720

Summaries for Ehlers-Danlos Syndrome

About this section
NIH Rare Diseases:45 Ehlers-danlos syndrome (eds) is a group of inherited connective tissue disorders that is caused by abnormalities in the structure, production, and/or processing of collagen. there are 6 major forms of eds: hypermobility type, classic type, vascular type, kyphoscoliosis type, arthrochalasia type, and dermatosparaxis type. although other forms of the condition exist, they are extremely rare and are not well-characterized. the signs and symptoms of eds vary by type and range from mildly loose joints to life-threatening complications. features shared by many types include joint hypermobility and soft, velvety skin that is highly elastic (stretchy) and bruises easily. changes (mutations) in a variety of genes may lead to eds; however, the underlying genetic cause in some families is unknown. depending on the subtype, eds may be inherited in an autosomal dominant or an autosomal recessive manner. there is no specific cure for eds. the treatment and management is focused on preventing serious complications and relieving associated signs and symptoms. last updated: 3/20/2016

MalaCards based summary: Ehlers-Danlos Syndrome, also known as eds, is related to ehlers-danlos syndrome, type iv and ehlers-danlos syndrome, cardiac valvular form. An important gene associated with Ehlers-Danlos Syndrome is COL3A1 (Collagen Type III Alpha 1), and among its related pathways are Cell adhesion_Endothelial cell contacts by non-junctional mechanisms and VEGFR3 signaling in lymphatic endothelium. Affiliated tissues include skin, bone and eye, and related mouse phenotypes are limbs/digits/tail and skeleton.

Disease Ontology:10 A collagen disease that is characterized by extremely flexible joints, elastic skin, and excessive bruising caused by a heritable defect in collagen synthesis, which leads to marked healing difficulties. EDS has five cardinal signs, which may be present to some degree in all of the subtypes. These five cardinal signs are skin fragility, blood vessel fragility, skin hyperelasticity, joint hypermobility, and characteristic subcutaneous nodules.

MedlinePlus:35 Ehlers-danlos syndrome (eds) is a group of inherited disorders that weaken connective tissues. connective tissues are proteins that support skin, bones, blood vessels, and other organs. eds usually affects your skin, joints and blood vessel walls. symptoms include loose joints fragile, small blood vessels abnormal scar formation and wound healing soft, velvety, stretchy skin that bruises easily there are several types of eds. they can range from mild to life-threatening. about 1 in 5,000 people has eds. there is no cure. treatment involves managing symptoms, often with medicines and physical therapy. it also includes learning how to protect your joints and prevent injuries.

Genetics Home Reference:23 Ehlers-Danlos syndrome is a group of disorders that affect the connective tissues that support the skin, bones, blood vessels, and many other organs and tissues. Defects in connective tissues cause the signs and symptoms of Ehlers-Danlos syndrome, which vary from mildly loose joints to life-threatening complications.

Wikipedia:68 Ehlers–Danlos syndrome (EDS) is an inherited connective tissue disorder with presentations that have... more...

Related Diseases for Ehlers-Danlos Syndrome

About this section

Diseases in the Ehlers-Danlos Syndrome family:

Ehlers-Danlos Syndrome, Type Vi Ehlers-Danlos Syndrome, Type Iv
Ehlers-Danlos Syndrome, Type Viic Ehlers-Danlos Syndrome, Type Viib
Ehlers-Danlos Syndrome, Type Viii Ehlers-Danlos Syndrome, Type Iii
Type I Ehlers-Danlos Syndrome Autosomal Recessive Type Iv Ehlers-Danlos Syndrome
Ehlers-Danlos Syndrome Type 5 Ehlers-Danlos Syndrome, Type Vii
Ehlers-Danlos Syndrome Type Via

Diseases related to Ehlers-Danlos Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 596)
idRelated DiseaseScoreTop Affiliating Genes
1ehlers-danlos syndrome, type iv35.3COL3A1, COL5A1
2ehlers-danlos syndrome, cardiac valvular form34.6COL1A1, COL1A2
3ehlers-danlos syndrome, classic type34.5COL1A1, COL1A2, COL3A1, COL5A1, COL5A2
4ehlers-danlos syndrome, type vi34.3CHST14, COL1A1, COL5A1, PLOD1
5ehlers-danlos syndrome, spondylocheirodysplastic type34.3CHST14, DSE
6ehlers-danlos syndrome, type viib13.1
7ehlers-danlos syndrome, type iii13.1
8ehlers-danlos syndrome, type viic13.1
9ehlers-danlos syndrome, type viii13.0
10ehlers-danlos syndrome progeroid type13.0
11ehlers-danlos syndrome, musculocontractural type12.9
12ehlers-danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss12.8
13spondylocheirodysplasia, ehlers-danlos syndrome-like12.8
14ehlers-danlos syndrome, musculocontractural type 112.8
15ehlers-danlos syndrome, progeroid type, 112.8
16ehlers-danlos syndrome, progeroid type, 212.8
17ehlers-danlos syndrome, fibronectinemic type12.8
18ehlers-danlos syndrome kyphoscoliosis type12.8
19ehlers-danlos syndrome, musculocontractural type 212.8
20ehlers-danlos syndrome due to tenascin x deficiency12.8
21ehlers-danlos syndrome, arthrochalasis type12.8
22ehlers-danlos syndrome, kyphoscoliotic and deafness type12.8
23ehlers-danlos syndrome, cardiac valvular type12.8
24x-linked ehlers-danlos syndrome12.8
25type i ehlers-danlos syndrome12.7
26ehlers-danlos syndrome, vascular-like type12.7
27ehlers-danlos syndrome, kyphoscoliotic form12.7
28ehlers-danlos syndrome, dysfibronectinemic type12.7
29ehlers-danlos syndrome type 512.6
30autosomal recessive type iv ehlers-danlos syndrome12.6
31ehlers-danlos syndrome, autosomal recessive, due to tenascin x deficiency12.5
32ehlers-danlos syndrome, classic type, col1a1-related12.5
33ehlers-danlos syndrome, classic type, col5a1-related12.5
34ehlers-danlos syndrome, classic type, col5a2-related12.5
35ehlers-danlos syndrome, type vii12.5
36ehlers-danlos syndrome type via12.5
37ehlers-danlos-like syndrome due to tenascin-x deficiency12.2
38occipital horn syndrome12.2
39heterotopia, periventricular, ed variant12.0
40familial joint instability syndrome12.0
41brittle cornea syndrome 112.0
42adducted thumbs dundar type11.6
43mounier-kuhn syndrome11.1
44prostatitis10.8
45hepatitis10.7
46leukemia10.7
47lymphoma10.7
48ehlers-danlos/osteogenesis imperfecta syndrome10.7
49melanoma10.7
50endotheliitis10.7

Graphical network of the top 20 diseases related to Ehlers-Danlos Syndrome:



Diseases related to ehlers-danlos syndrome

Symptoms for Ehlers-Danlos Syndrome

About this section

Drugs & Therapeutics for Ehlers-Danlos Syndrome

About this section

Drugs for Ehlers-Danlos Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1CeliprololPhase 42
2Peripheral Nervous System AgentsPhase 418510
3Vasodilator AgentsPhase 42926
4Adrenergic AgentsPhase 44204
5Antihypertensive AgentsPhase 4, Phase 33618
6Neurotransmitter AgentsPhase 414795
7Anti-Arrhythmia AgentsPhase 42371
8Adrenergic AntagonistsPhase 41253
9Adrenergic beta-1 Receptor AntagonistsPhase 4292
10Adrenergic beta-AntagonistsPhase 4979
11
Irbesartanapproved, investigationalPhase 397138402-11-63749
Synonyms:
138402-11-6
2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(4.4)non-1-en-4-one
2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[4.4]non-1-en-4-one
2-Butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-[ p -( o -1 H -tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one
2-butyl-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[
2-butyl-3-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[
2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one
8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one
AC-537
AC1L1GMK
Aprovel
Avalide
Avapro
Avapro (TN)
BIDD:GT0347
BMS 186295
BMS Brand of Irbesartan
BMS-186295
BMS-186295, SR-47436, Aprovel, Karvea, Irbesartan
BRD-K60038276-001-02-5
BSPBio_002687
Bio-0053
Bristol Myers Brand of Irbesartan
C07469
C081309
C25H28N6O
CHEBI:5959
CHEMBL1513
CID3749
CPD000466306
D00523
DB01029
HMS1922J05
HMS2051L08
HMS2093E16
 
I06-0690
Irbesarran
Irbesartan
Irbesartan (JAN/USAN/INN)
Irbesartan [USAN:INN]
Irbesartan [Usan:Inn]
Irbetan
Jsp002315
KBio2_002231
KBio2_004799
KBio2_007367
KBio3_001907
KBioGR_001603
KBioSS_002231
Karvea
L000319
LS-60064
Lrbesartan
MLS000759408
MLS001424099
MolPort-003-666-550
NCGC00095122-01
NCGC00095122-02
NCGC00095122-03
S1507_Selleck
SAM001246548
SMR000466306
SPBio_001889
SPECTRUM1504259
SR 47436
SR-47436
STK645362
Sanofi Winthrop Brand of Irbesartan
Spectrum2_001675
Spectrum3_000994
Spectrum4_001122
Spectrum5_001288
Spectrum_001751
TL8000875
UNII-J0E2756Z7N
irbesartan
12Serine Proteinase InhibitorsPhase 3705
13Trace ElementsPhase 33900
14Protease InhibitorsPhase 34558
15
CopperPhase 31587440-50-827099
Synonyms:
 
Copper
Cu
16Vasoconstrictor AgentsPhase 31303
17
Angiotensin IIPhase 3103368521-88-0, 11128-99-7172198, 65143
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
Ang II
Angiotensin 2
Angiotensin II (human)
 
Angiotensin II (mouse)
Angiotonin
Asp-arg-val-TYR-ile-his-pro-phe
Human angiotensin II
Hypertensin
Ile(5)-angiotensin II
18MicronutrientsPhase 33901
19Angiotensin II Type 1 Receptor BlockersPhase 3949
20Angiotensin Receptor AntagonistsPhase 31039
21AngiotensinogenPhase 31032
22HIV Protease InhibitorsPhase 34558
23serineNutraceuticalPhase 3770
24histidineNutraceuticalPhase 336
25
Riboflavinapproved, nutraceutical15083-88-5493570
Synonyms:
(-)-Riboflavin
1-Deoxy-1-(3,4-dihydro-7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10(2H)-yl)-D-ribitol
1-Deoxy-1-(7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2H)-yl)pentitol
6,7-Dimethyl-9-D-ribitylisoalloxazine
6,7-Dimethyl-9-ribitylisoalloxazine
7,8-Dimethyl-10-(D-ribo-2,3,4,5-tetrahydroxypentyl)-Benzo[g]pteridine-2,4(3H,10H)-dione
7,8-Dimethyl-10-(D-ribo-2,3,4,5-tetrahydroxypentyl)benzo[g]pteridine-2,4(3H,10H)-dione
7,8-Dimethyl-10-(D-ribo-2,3,4,5-tetrahydroxypentyl)isoalloxazine
7,8-Dimethyl-10-ribitylisoalloxazine
Beflavin
Beflavine
Benzo[g]pteridine riboflavin deriv.
E 101
Flavaxin
Flavin BB
Flaxain
Food Yellow 15
Hyre
Lactobene
 
Lactoflavin
Lactoflavine
Ribipca
Ribocrisina
Riboderm
Riboflavin
Riboflavin phosphate sodium dihydrate
Riboflavina
Riboflavine
Riboflavinum
Ribosyn
Ribotone
Ribovel
Russupteridine yellow III
San Yellow B
Vitaflavine
Vitamin B2
Vitamin G
Vitasan B2
e101
26
Folic Acidapproved, nutraceutical292459-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic Acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
 
Folsaeure
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
27Immunoglobulins4477
28Antibodies4477
29Vitamins3857
30Dermatologic Agents4555
31Vitamin B Complex2847
32Photosensitizing Agents374
33Vitamin B9Nutraceutical2924
34Vitamin B2Nutraceutical150
35FolateNutraceutical2924

Interventional clinical trials:

(show all 23)
idNameStatusNCT IDPhase
1Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular TypeCompletedNCT00190411Phase 4
2Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)RecruitingNCT02597361Phase 3
3Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper DeficiencyRecruitingNCT00811785Phase 3
4Mind-Body Therapy for Pain in Ehlers-Danlos SyndromeCompletedNCT00001966Phase 2
5Obstructive Sleep Apnoea in Ehlers-Danlos SyndromeCompletedNCT02435745
6Biomarkers in Vascular Ehlers-Danlos SyndromeCompletedNCT02165085
7Head Circumference Growth in Children With Ehlers-Danlos Syndrome Who Develop Dysautonomia Later in LifeCompletedNCT01367977
8Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI)CompletedNCT01356134
9Study of Heritable Connective Tissue DisordersCompletedNCT00001641
10Studies of Heritable Disorders of Connective TissueCompletedNCT00270686
11IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos PatientsCompletedNCT01446783
12Non-Invasive Quantitative Imaging of Human Local Arterial Wall Elasticity Using Supersonic Shear ImagingCompletedNCT01096264
13Obstructive Sleep Apnoea in Children and Adolescents With Ehlers-Danlos SyndromeRecruitingNCT02712060
14Wearing a Compression Garment for Patients With Hypermobility Type of Ehlers-Danlos SyndromeRecruitingNCT02144532
15Risk of Rupture of Aneurysms of the Thoracic Ascending Aorta (ATA) From the Dynamic ImagingRecruitingNCT02538822
16Assessment of Antibodies and Inflammatory Markers in Postural Tachycardia SyndromeRecruitingNCT02196376
17Development of a Blood Test for Marfan SyndromeRecruitingNCT02148900
18Investigation of Hypermobility, Biomarkers, and Pain Generators in Chronic Pain PatientsRecruitingNCT02761928
19Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy SyndromesRecruitingNCT02213484
20National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular ConditionsActive, not recruitingNCT01322165
21Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VIEnrolling by invitationNCT01307527
22Origins and Impact of EDS in Connective Tissues and SkinNot yet recruitingNCT02721797
23Head Circumference Growth in Children Who Develop Multiple Sclerosis Later in LifeWithdrawnNCT01377805

Search NIH Clinical Center for Ehlers-Danlos Syndrome


Cochrane evidence based reviews: ehlers-danlos syndrome

Genetic Tests for Ehlers-Danlos Syndrome

About this section

Anatomical Context for Ehlers-Danlos Syndrome

About this section

MalaCards organs/tissues related to Ehlers-Danlos Syndrome:

33
Skin, Bone, Eye, Breast, Lung, Testes, Endothelial

Animal Models for Ehlers-Danlos Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Ehlers-Danlos Syndrome:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053718.4CHST14, COL1A1, COL1A2, DSE, PLOD1
2MP:00053907.4ADAMTS2, CHST14, COL1A1, COL1A2, COL5A2, PLOD1
3MP:00053786.4ADAMTS2, CHST14, COL1A1, COL1A2, COL3A1, COL5A1
4MP:00107716.4ADAMTS2, CHST14, COL1A1, COL1A2, COL3A1, COL5A1

Publications for Ehlers-Danlos Syndrome

About this section

Articles related to Ehlers-Danlos Syndrome:

(show top 50)    (show all 815)
idTitleAuthorsYear
1
Trim37-deficient mice recapitulate several features of the multi-organ disorder Mulibrey nanism. (27044324)
2016
2
Novel bio-spectroscopic imaging reveals disturbed protein homeostasis and thiol redox with protein aggregation prior to hippocampal CA1 pyramidal neuron death induced by global brain ischemia in the rat. (26454085)
2015
3
Granular cell tumor presenting as a large leg mass. (25692157)
2014
4
The characteristics of ascites in patients with POEMS syndrome. (23811954)
2013
5
Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. (23871780)
2013
6
Hypothalamic Immunopathology in Anti-Ma-Associated Diencephalitis With Narcolepsy-Cataplexy. (23939463)
2013
7
Indoxyl sulfate signals for rapid mRNA stabilization of Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 2 (CITED2) and suppresses the expression of hypoxia-inducible genes in experimental CKD and uremia. (23792300)
2013
8
Bouveret's syndrome: successful endoscopic treatment of gastric outlet obstruction caused by an impacted gallstone. (22414360)
2012
9
Glucocorticoid receptor-DNA interactions: binding energetics are the primary determinant of sequence-specific transcriptional activity. (22698871)
2012
10
An evidence-based approach to craniosynostosis. (21285796)
2011
11
NBS1 recruits RAD18 via a RAD6-like domain and regulates Pol I^-dependent translesion DNA synthesis. (21884979)
2011
12
Structural basis for Par-4 recognition by the SPRY domain- and SOCS box-containing proteins SPSB1, SPSB2, and SPSB4. (20561531)
2010
13
White matter integrity is associated with treatment outcome measures in cocaine dependence. (20393459)
2010
14
Automated mass action model space generation and analysis methods for two-reactant combinatorially complex equilibriums: an analysis of ATP-induced ribonucleotide reductase R1 hexamerization data. (20003203)
2009
15
Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use. (19244569)
2009
16
CAG repeat variation in the mtDNA polymerase gamma is not associated with oligoasthenozoospermia. (18798765)
2009
17
Triple A syndrome with ophthalmic manifestations in two siblings. (17595484)
2007
18
Optos Panoramic200A fluorescein angiography for proliferative diabetic retinopathy with asteroid hyalosis. (17564923)
2007
19
Absolute quantification in dopaminergic neurotransmission SPECT using a Monte Carlo-based scatter correction and fully 3-dimensional reconstruction. (16157533)
2005
20
Inflammatory chemokine expression in the peripheral blood of neonates with perinatal asphyxia and perinatal or nosocomial infections. (16188792)
2005
21
New AlstrAPm syndrome phenotypes based on the evaluation of 182 cases. (15795345)
2005
22
Hepatitis C virus core protein exerts an inhibitory effect on suppressor of cytokine signaling (SOCS)-1 gene expression. (16083990)
2005
23
Association between the APOE*4 allele and atherosclerosis is age dependent among Argentine males. (16201140)
2005
24
Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. (16081635)
2005
25
Vitamin D receptor polymorphisms and susceptibility to tuberculosis in West Africa: a case-control and family study. (15478069)
2004
26
The transcription factor CCAAT-binding factor CBF/NF-Y and two repressors regulate the core promoter of the human pro-alpha3(V) collagen gene (COL5A3). (15316020)
2004
27
Regulation of NGFI-B expression during the ovulatory process. (12770726)
2003
28
Dexamethasone and retinoic acid differentially regulate growth and differentiation in an immortalised human clonal bone marrow stromal cell line with osteoblastic characteristics. (12234625)
2002
29
Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation. (11777191)
2002
30
ARAP1: a point of convergence for Arf and Rho signaling. (11804590)
2002
31
Factors affecting the PSA:alpha 1 antichymotrypsin/total PSA ratio]. (11512259)
2001
32
Mutation of three critical amino acids of the N-terminal domain of IGF-binding protein-3 essential for high affinity IGF binding. (11600567)
2001
33
Circulation of progenitor cells after intensive chemotherapy followed by combination G-CSF and EPO in breast carcinoma. (9473775)
1997
34
Heparins designed to specifically inhibit platelet interactions with von Willebrand factor. (8598091)
1996
35
Subcutaneous dirofilariasis in Collier County, Florida, USA. (7611540)
1995
36
An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. (8063741)
1994
37
Relationships between serum lipid peroxide level (serum TBA level) and smoking, alcohol drinking, food frequency, serum vitamin C and E in subjects with multiphasic screening]. (8025308)
1994
38
Can malnutrition be prevented in patients on chronic extracorporeal dialysis?]. (7701410)
1994
39
The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth. (8186658)
1994
40
Normal plasma levels of IGF binding protein in Perthes' disease. Follow-up of previous report. (7694440)
1993
41
Radionuclide evaluation of unilateral pulmonary vein stenosis. Correlation with chest roentgenogram and clinical profiles. (3295141)
1986
42
Florid reactive periostitis of the proximal phalanx. Case report. (4019546)
1985
43
Alcoholic cardiomyopathy. (890189)
1977
44
ACUTE COR PULMONALE AND SHOCK. (14348043)
1965
45
Squamous papillomatosis of the stomach, a new pathologic entity: report of a case. (14018854)
1962
46
An evaluation of the etiologic survey in chorioretinitis. (13705282)
1961
47
48
49
50

Variations for Ehlers-Danlos Syndrome

About this section

Expression for genes affiliated with Ehlers-Danlos Syndrome

About this section
Search GEO for disease gene expression data for Ehlers-Danlos Syndrome.

Pathways for genes affiliated with Ehlers-Danlos Syndrome

About this section

Pathways related to Ehlers-Danlos Syndrome according to GeneCards Suite gene sharing:

(show all 19)
idSuper pathwaysScoreTop Affiliating Genes
19.8COL1A1, COL1A2
29.8COL1A1, COL1A2
39.8COL1A1, COL1A2
49.5COL1A1, COL1A2, COL3A1
59.5COL1A1, COL1A2, COL3A1
6
Show member pathways
9.5COL1A1, COL1A2, COL3A1
79.5COL1A1, COL1A2, COL3A1
89.5COL1A1, COL1A2, COL3A1
99.5COL1A1, COL1A2, COL3A1
109.5COL1A1, COL1A2, COL3A1
11
Show member pathways
9.5COL1A1, COL1A2, TNXB
128.9COL1A1, COL1A2, COL3A1, COL5A1, COL5A2
13
Show member pathways
8.9COL1A1, COL1A2, COL3A1, COL5A1, COL5A2
14
Show member pathways
8.9B4GALT7, CHST14, DSE
15
Show member pathways
8.7COL1A1, COL1A2, COL3A1, COL5A1, COL5A2, TNXB
16
Show member pathways
8.4B3GALT6, B4GALT7, CHST14, DSE
17
Show member pathways
8.4B3GALT6, B4GALT7, CHST14, DSE
18
Show member pathways
8.3ADAMTS2, COL1A1, COL1A2, COL3A1, COL5A1, COL5A2
19
Show member pathways
8.0ADAMTS2, COL1A1, COL1A2, COL3A1, COL5A1, COL5A2

GO Terms for genes affiliated with Ehlers-Danlos Syndrome

About this section

Cellular components related to Ehlers-Danlos Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1collagen type I trimerGO:00055849.8COL1A1, COL1A2
2extracellular regionGO:00055768.9ADAMTS2, COL5A1, COL5A2, TNXB

Biological processes related to Ehlers-Danlos Syndrome according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1extracellular fibril organizationGO:004320610.4B4GALT7, TNXB
2blood vessel developmentGO:000156810.2COL1A1, COL5A1
3platelet activationGO:00301689.8COL1A1, COL1A2, COL3A1
4collagen fibril organizationGO:00301999.7ADAMTS2, COL1A1, COL5A2, TNXB
5skin morphogenesisGO:00435899.7COL1A1, COL1A2
6chondroitin sulfate metabolic processGO:00302049.6B4GALT7, CHST14
7cellular response to amino acid stimulusGO:00712309.6COL1A1, COL1A2, COL3A1
8skin developmentGO:00435889.3COL1A1, COL3A1, COL5A1, COL5A2
9extracellular matrix disassemblyGO:00226178.9COL1A1, COL1A2, COL3A1, COL5A1, COL5A2
10collagen catabolic processGO:00305748.7ADAMTS2, COL1A1, COL1A2, COL3A1, COL5A1, COL5A2
11extracellular matrix organizationGO:00301988.6ADAMTS2, COL1A1, COL3A1, COL5A1, TNXB

Molecular functions related to Ehlers-Danlos Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1integrin bindingGO:00051789.9COL5A1, TNXB

Sources for Ehlers-Danlos Syndrome

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet